Trial Profile
Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLL2-BIO
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 14 Dec 2021 Results of polled analysis of pts aged 80 years or older in 6 phase II and III studies of the German CLL Study Group (GCLLSG) in the frontline-setting to elucidate outcomes of targeted treatments with regard to relevant clinical endpoints including overall survival and causes of death presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 04 Jun 2021 Results (n=189) of pooled analysis of three prospective phase-II trials (NCT02345863, NCT02401503, NCT02689141) assessing the feasible in a population with the highest risk of an early relapse, published in the Blood.